Ariel Feinerman is the Chief Science Officer at IntraClear Biologics, based in Saint Petersburg. With a background in molecular biology, Feinerman is dedicated to advancing treatments for age-related diseases and improving human longevity. Feinerman's expertise spans nanomedicine and bioengineering. Previously, he held roles as Deputy Chief Editor at Future Collector and worked as a Bioengineering Consultant. Feinerman’s work is driven by a vision to achieve Longevity Escape Velocity, aiming to overcome the limitations of aging and disease.